Does anyone have the removed Breezula phase II 12 month baseline comparison results? Research/Science 1/20/2021
The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.
View this post in the Community →
Similar Community Posts Join
5 / 387 resultscommunity WHERE to buy cb 03 01 before breezula comes out, after DUT.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
community What the Breezula Phase III results mean & realistic timeline
Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
community Cassiopea announces completion of recruitment of Phase II dose ranging trial of Breezula (CB-03-01) for androgenic alopecia
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
community Binding affinity does not equal potency for anti androgens? Comparing pyrilutimide to cb-03-01
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
Related Research
6 / 16 results
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Biotechs target stagnant baldness market
New drug shows promise for better hair growth in baldness treatment.
research Experimental and early investigational drugs for androgenetic alopecia
New hair loss treatments may include topical medications, injections, and improved transplant methods.
research Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options
New treatments for hair loss may target specific pathways and generate new hair follicles.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.